4
Changes in Ownership
Contineum Therapeutics, Inc. Filed Acc 0001437749-26-005892
CEO and President sold 7,100 shares at an average $16.02 ($113,728)
- CEO and President acquired 7,100 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Stengone Carmine N. · CEO and President
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-02-24 | Exercise or conversion : show line 1 in the form 10b5-1 | +4,400 | $1.26 | $5,544 | 19,354 | D |
| 2026-02-24 | Sale : show line 2 in the form 10b5-1 | −4,400 | $16.02 | $70,486 | 14,954 | D |
| 2026-02-25 | Exercise or conversion : show line 3 in the form 10b5-1 | +2,700 | $1.26 | $3,402 | 17,654 | D |
| 2026-02-25 | Sale : show line 4 in the form 10b5-1 | −2,700 | $16.02 | $43,242 | 14,954 | D |
| Open-market sales · 7,100 sh · avg $16.02 · $113,728 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-02-24 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (right to buy) | −4,400 | 123,617 | D |
| 2026-02-25 | Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (right to buy) | −2,700 | 120,917 | D |
Loading xslF345X05/rdgdoc.xml…